Physician profile
Joseph Weinstein
NPI 1013915974
$7,174.68
in general payments reported to CMS, 2019-2025
23 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $469 · 2021: $766 · 2022: $1,334 · 2023: $1,392 · 2024: $915 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,428.06 | 2019-2025 | Simbrinza, Rocklatan, Rhopressa |
| Abbvie INC. | $1,140.32 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Arteriocyte Medical Systems, INC. | $532.67 | 2021-2023 | Magellan |
| Bausch & Lomb Americas INC. | $491.29 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Aerie Pharmaceuticals, INC. | $463.94 | 2019-2021 | |
| Glaukos Corporation | $413.88 | 2019-2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $404.29 | 2021-2024 | Cequa |
| Allergan, INC. | $372.27 | 2019-2022 | |
| Oyster Point Pharma, INC. | $364.31 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $312.88 | 2019 | |
| Kala Pharmaceuticals, INC. | $308.54 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $189.83 | 2019-2021 | |
| Genentech USA, INC. | $125.00 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $122.19 | 2024 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $118.73 | 2023 | Syfovre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.65 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $105.93 | 2023 | Acthar |
| Sight Sciences, INC. | $38.10 | 2022-2023 | Tearcare System |
| Harrow Eye, LLC | $32.68 | 2025 | Vevye |
| Rayner Intraocular Lenses Limited | $25.35 | 2024 | Omidria |
| Shire North American Group INC | $23.51 | 2019 | |
| Amgen INC. | $22.83 | 2025 | Tepezza |
| Thea Pharma INC. | $20.43 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.